Bristol-myers Squibb Compnay

Bristol-myers Squibb Pharma Company

Other

Dupont Pharmaceuticals Company

E.i. Dupont De Nemours and Company

Carl P Decicco

Jingwu Duan

Mimi Lifen Quan

James R Corte

Chu-Biao Xue

Thomas P Maduskuie, Jr

Wu Yang

Joanne M Smallheer

Yufeng Wang

Karen Anita Rossi

Matthew Ernst Voss

Zilun Hu

Yoon T Jeon

Tianan Fang

Ronald L Magolda

Donald J P Pinto

Timothy C Burn

Cailan Wang

Micky Daniel Tortorella

James M Trzaskos

Robert A Copeland

Elizabeth C Arner

Ruiqin Liu

Michael A Pratta

Xiaohua He

Fude Yang

Kimberly A Solomon

Lihua Chen

Zelda Rakowitz Wasserman

David J Nelson

Robert J Cherney

Ruth Richmond Wexler

Gregory R Ott

Zhonghui Lu

Wenqing Yao

Andrew Paul Combs

Milind Rajopadhye

Thomas W Hudyma

Xiaofan Zheng

Eldon Scott Priestley

William F DeGrado

Andrew J Tebben

Lorin A Thompson, Iii

John A Barrett

Irina Cipora Jacobson

E Scott Priestley

Ying Song

Bryan W King

Donald Jp Pinto

Alan P Carpenter Jr

Chu-Bio Xue

Elizabeth Arner

David Nelson

The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Macrocycles as factor xia inhibitors

Macrocycles as factor XIA inhibitors

Macrocycles as factor XIa inhibitors

The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

There is provided a series of novel substituted gamma-lactams of Formula (I) wherein R, R, R, Rand Rare defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by &#x3b2;-secretase and, more specifically, inhibit the production of A&#x3b2;-peptide. The present invention is directed to compounds useful in the treatment of neurological disorders related to &#x3b2;-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

Gamma-lactams as beta-secretase inhibitors

The present invention relates to lactams of Formula (I):or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HCV NS3 protease, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.

Lactam inhibitors of Hepatitis C virus NS3 protease

The invention is directed to the family of aggrecan degrading metallo proteases (ADMPs) that exhibit the ability to cleave the aggrecan core protein between amino acid residues Glu-Ala. The invention encompasses the nucleic acids encoding such enzymes, processes for production of recombinant ADMPs, compositions containing such enzymes, and the use of these enzymes in various assays and for the development of novel inhibitors for use as therapies for diseases involving aggrecanase-mediated degradation of cartilage or other aggrecanase-associated diseases.

Antibodies to aggrecan-degrading metalloprotease and diagnostic methods using same

Thus the present invention describes novel compounds comprising 1-10 targeting moieties; a chelator (Ch); and 0-1 linking groups (Ln) between the targeting moiety and chelator; wherein the targeting moiety is a matrix metalloproteinase inhibitor; and wherein the chelator is capable of conjugating to a cytotoxic radioisotope. The present invention also provides novel compositions of the compounds of the invention, kits and their uses in treatment of diseases associated with MMPs.

Matrix metalloproteinase inhibitors

The present application describes novel cyclic &#x3b2;-amino acid derivatives of formula I:or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NR, and S(O), and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as metalloprotease and/or as TNF-&#x3b1; inhibitors.

Cyclic &#x3b2;-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-&#x3b1;

The present application describes novel bicyclic lactam derivatives of formula I:or pharmaceutically acceptable salt forms thereof, wherein A, B, C, D, R, and Rare defined in the present specification, which are useful as metalloprotease, TNF-&#x3b1;, and/or aggrecanase inhibitors.

Bicyclic lactam derivatives as inhibitors of matrix metalloproteinases and/or TNF-&#x3b1; converting enzyme (TACE)

Growing community of inventors

Kennett Square, PA, United States of America

Carl P Decicco